Abstral® is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain  in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral® allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.

Short facts
Technology	Sublingual
Indication	Breakthrough cancer pain
Market approvals	US, EU, RoW among others Japan, Australia, Saudi Arabia and South Korea
Commercial rights	RoW, Kyowa Kirin
Partner
Patent protection	On RoW markets until 2024. For the US and the EU the patents expired in September 2019.

The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral® is currently available in key markets such as Japan, Australia and South-Korea. Globally, the market for Abstral® has continued to grow rapidly over the years.